Genocea Biosciences, Inc. (GNCA) |
|
0.0001 -0.001 (-85.71%)
|
12-22 14:54 |
|
Open: |
0.0007 |
Pre. Close: |
0.0039 |
|
High:
|
0.0001 |
Low:
|
0.0001 |
|
Volume:
|
30,268 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-03-03 4:49:50 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0 One year: 0 |
| Support: |
Support1: 0 Support2: 0 |
| Resistance: |
Resistance1: 0 Resistance2: 0 |
| Pivot: |
0 |
| Moving Average: |
MA(5): 0 MA(20): 0
MA(100): 0  MA(250): 0.19 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 67.7 %D(3): 45.5 |
| RSI: |
RSI(14): 59.9 |
| 52-week: |
High: 1.45 Low: 0 |
| Average Vol(K): |
3-Month: 45 (K) 10-Days: 21 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GNCA ] has closed below upper band by 15.9%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0 - 0 |
0 - 0 |
|
Low:
|
0 - 0 |
0 - 0 |
|
Close:
|
0 - 0 |
0 - 0 |
|
Company Description |
|
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. |
Headline News |
Wed, 15 Jun 2022
Should You Buy Genocea Biosciences Inc (GNCA) Stock After it Has Fallen 0.00% in a Week? - InvestorsObserver
Wed, 25 May 2022
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors ... - InvestorPlace
Tue, 24 May 2022
Genocea Announces Wind Down of Operations and Delisting From ... - GlobeNewswire
Tue, 24 May 2022
Genocea closes up shop after cash reserves dry up - FierceBiotech
Thu, 28 Apr 2022
Genocea Initiates Restructuring and Announces Plan to Explore ... - GlobeNewswire
Fri, 08 Apr 2022
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1 ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
59 (M) |
|
% Held by Insiders
|
5.411e+007 (%) |
|
% Held by Institutions
|
6.2 (%) |
|
Shares Short
|
2,970 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.567e+007 |
|
EPS Est Next Qtl
|
-0.38 |
|
EPS Est This Year
|
-1.92 |
|
EPS Est Next Year
|
-1.12 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
958.8 |
|
Return on Equity (ttm)
|
-57.6 |
|
Qtrly Rev. Growth
|
1.91e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-328.62 |
|
EBITDA (p.s.)
|
1.025e+006 |
|
Qtrly Earnings Growth
|
-0.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-48 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.02 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.64e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-05-21 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
